Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Summary

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood cells back to the person.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Endocrine Tumors
• Non-Small Cell Lung Cancer
• Ovarian Cancer
• Breast Cancer
• Gastrointestinal/Genitourinary Cancers
• Neuroendocrine Tumors
• Multiple Myeloma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 72 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

National Cancer Institute (NCI)

Last updated on ClinicalTrials.gov

September 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites